Leadership

Roger Jeffs, Ph.D. joined Liquidia as its CEO in 2022 after serving on the company’s Board of Directors beginning in 2020. In addition, Roger is the Vice-Chairman and Co-Founder of Kryia Therapeutics, a company focused on accelerating the development of innovative gene therapy programs for both rare and prevalent diseases. He currently serves on the Boards of Liquidia (LQDA) and Axsome Therapeutics (AXSM), and previously served on the Board of Directors of United Therapeutics (UTHR) from 2001-2016, Dova Pharmaceuticals (DOVA) from 2017-2019, Sangamo Therapeutics (SGMO) from 2017-2019, Axovant Gene Therapies (AXGT) from 2017-2019, and Albireo Pharma (ALBO) from 2017-2021.

Roger retired as President & Co-CEO of United Therapeutics Corporation in 2016 after an 18-year tenure. He joined United Therapeutics during its start-up phase in 1998 as director of research, development and medical, and served as its President and Chief Operating Officer from 2001 to 2014, and President & Co-CEO from 2015-2016. While at United Therapeutics, Roger helped lead its IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to a >20% CAGR, a $1.5B annual revenue run rate and a $8B peak market cap. During his tenure, United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work. Previous to his roles at United Therapeutics, Roger held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.

In 2015, Roger received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in "recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children." He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine.

Michael Kaseta joined Liquidia in 2020 where he serves as Chief Operating Officer and Chief Financial Officer. His extensive background spans corporate finance, business strategy and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Prior to Liquidia, Michael served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, he served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent 11 years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and more than 100 products across eight therapeutic areas. Michael holds a Bachelor of Business Administration in accounting from James Madison University, is a Certified Public Accountant (inactive) licensed in the state of New Jersey and serves on the Board of Directors at Heron Therapeutics and Bryn Pharma.

Rajeev Saggar, M.D. joined Liquidia in 2022 where he serves as the company’s Chief Medical Officer. He brings more than 20 years of experience as a practicing pulmonologist to his role at Liquidia where he oversees all aspects of research, clinical development, medical affairs and regulatory affairs. Previously, Rajeev served as Vice President of Clinical Development at Theravance Biopharma with oversight of all phases of clinical development across its respiratory disease portfolio, including pulmonary fibrosis, allograft rejection, asthma, COPD and COVID-19. Prior to this, he served as Interim Chief of the Division of Pulmonary Critical Care at University of Arizona, College of Medicine, Phoenix, and as the Medical Director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix. Rajeev also served as a Principal Investigator in the pivotal INSPIRE study of YUTREPIA initiated in 2018. He has authored more than 60 peer-reviewed publications with scientific interests including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Rajeev holds a Doctor of Medicine degree from the University of California, Irvine. He completed his residency in Internal Medicine and fellowship in Pulmonary & Critical Care at the University of California, Irvine, as well as subspecialty training in pulmonary hypertension and lung transplantation at University of California, San Diego and University of California, Los Angeles, respectively.

Scott Moomaw, MBA joined Liquidia in 2020 where he serves as Chief Commercial Officer (CCO). Scott is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and organizations. He joined Liquidia from RareGen, which he co-founded, to commercialize Treprostinil Injection for pulmonary arterial hypertension (PAH). Prior to RareGen, Scott was Vice President of Marketing at Opko Health and United Therapeutics where he was responsible for Remodulin® (parenteral treprostinil), Tyvaso® (inhaled treprostinil) and Orenitram® (oral treprostinil) for PAH. Scott also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over 10 years. He holds a Master of Business Administration from the University of Michigan and a Bachelor of Science from Miami University.

Jason Adair joined Liquidia in 2016 where he serves as Chief Business Officer. In this role, he is responsible for corporate development activities including strategy, investor relations, communications and the pursuit of collaboration and licensing opportunities for the company. Prior to joining Liquidia, Jason led business development efforts at BioCryst Pharmaceuticals as its Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. Jason also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Jason worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He holds a Master of Business Administration from the Tuck School of Business at Dartmouth College and a Bachelor of Science in Chemistry from Wake Forest University.

Rusty Schundler joined Liquidia in 2021 where he serves as General Counsel and Corporate Secretary. From 2014 to 2021, Rusty served as General Counsel at PBM Capital Group, a healthcare investment firm, where he managed all legal matters for PBM and its subsidiaries. Prior to PBM, he was a corporate attorney with the law firms of Woods Rogers PLC and McGuireWoods LLP from 2001 to 2014, where he specialized in mergers and acquisitions, corporate financings and general corporate matters. Rusty also served as adjunct faculty at the University of Virginia School of Law from 2011 to 2014, where he oversaw the Transactional Law Clinic. Rusty is a member of the Virginia bar and holds a Bachelor of Arts in history and economics from the University of Virginia and a Doctor of Jurisprudence from the University of Virginia School of Law.

Sarah Krepp joined Liquidia in 2023 where she serves as Chief Human Resources Officer. She brings more than 19 years of experience in consulting, start-ups, mid-sized pharmaceuticals, and large clinical research organizations to her role at Liquidia. Previously, Sarah held progressive HR leadership roles at PRA, Salix, Chimerix, Istari Oncology, and most recently as Head of People and Culture for Fujifilm Diosynth Biotechnologies. She began her career working in the genetics laboratory for Bayer (later Talecris), before transitioning into the field of human resources. Sarah holds a Bachelor of Science in Biology from North Carolina State University and has specialized training in Executive Compensation and Organizational Psychology.

Dana Boyle joined Liquidia in 2021 where she serves as Chief Accounting Officer. With approximately 20 years of experience, Dana brings deep knowledge in accounting, financial planning and analysis, and business operations to her role at Liquidia. Previously, Dana held progressive financial roles at various startups and mid-sized life-science companies including Aerami Therapeutics, Aralez Pharmaceuticals and Iveric Bio. She began her career in Audit & Assurance and Mergers & Acquisitions Transaction Services at Deloitte. Dana holds a Bachelor of Science in accounting from Rutgers University and is a CPA licensed in the state of New York.

Sanjeev Khindri, MB, ChB, joined Liquidia in 2025 where he serves as  Chief Development Officer. In this role, Sanjeev leads and supports the company's development programs in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). He brings over 17 years of clinical development experience working across all phases of development from first-in-man to pivotal registrational, working in asthma, chronic obstructive pulmonary disorder (COPD), idiopathic pulmonary fibrosis (IPF), PAH and a number of rare and ultra-rare conditions as lymphangioleiomyomatosis (LAM), myelofibrosis and activated phosphoinositide 3-kinase delta syndrome (APDS). Sanjeev has taken a number of drugs to market in pediatric asthma and COPD. Prior to joining Liquidia, Sanjeev served as EVP Executive Vice President, Clinical Development for Aerovate Therapeutics where he led a large, complex, global Phase 2 study in adult patients with PAH. Prior to Aerovate, he held increasingly senior roles in clinical development across a number of both large and small pharmaceutical companies, including Novartis, GSK, Janssen and Galecto. He Sanjeev has authored more than 25 peer-reviewed publications with scientific interests including COPD, pediatric asthma and IPF. Sanjeev He holds a degree in medicine from the University of Liverpool, UK. He Sanjeev completed his residency in Internal Medicine in Liverpool and specialty training in clinical pharmacology and toxicology from King's College, London, UK and was in full-time clinical practice in acute and general medicine for 12 years.

Harold Alterson joined Liquidia in 2025 and serves as Senior Vice President of Technical Operations, where he leads the company’s internal manufacturing and quality operations supporting both clinical development and commercial execution. He has more than 25 years of experience across clinical-stage and commercial biopharmaceutical organizations, with a focus on advancing manufacturing and quality capabilities to support product approvals, commercial launches, and increasing operational complexity. Prior to joining Liquidia, Harold served as Chief Quality Officer at Humacyte, establishing quality capabilities to support FDA approval of a first-in-class regenerative medicine product. Prior to Humacyte, he held increasingly senior roles in Quality Control and Quality Assurance across multiple companies, including Kriya Therapeutics, bluebird bio, Biogen and Novartis. Harold holds a Bachelor of Science degree in Microbiology from Montana State University and contributes to the industry as a member of the Board of Directors of the North Carolina Life Sciences Organization.

Frank Bartolini, MSA joined Liquidia in 2021 where he serves as Senior Vice President of Market Access. With more than 20 years of experience in the biopharmaceuticals industry, Frank brings extensive experience developing and implementing proven tactics to the management of Liquidia’s market access strategy where he supports maximizing the accessibility of new product launches and the value of established products. Previously, Frank worked at Ironshore where he led its market access team from August 2019 to May 2021. Prior to this, Frank was an initial member of the RareGen team where he supported the build-out of the organization and the launch of Treprostinil Injection for pulmonary arterial hypertension (PAH). Frank holds a Master of Science in Accountancy from Western Michigan University and a Bachelor of Science from Central Michigan University.

Gareth Gwyn joined Liquidia in 2023 where he serves as Senior Vice President of Medical Affairs. In this role, Gareth leads the company’s medical strategy across pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and works closely with cross-functional partners to ensure that high-quality scientific evidence is translated into meaningful clinical understanding, enabling healthcare providers to deliver the best possible care to patients living with PAH and PH-ILD. He is also responsible for advancing Medical Affairs activities supporting YUTREPIA® and Liquidia’s proprietary PRINT® technology, with a focus on improving patient care and clinical outcomes. With more than two decades of experience in pulmonary vascular disease and Medical Affairs leadership, Gareth has dedicated his career to addressing unmet patient needs and advancing therapies that meaningfully improve quality of life. He has held senior roles across multiple biopharmaceutical companies, partnering with clinicians, investigators and patient advocacy organizations to support evidence generation, disease awareness and access to innovative treatments. Gareth holds a Bachelor of Science in Microbiology from Dalhousie University.  

Michael Hunter, M.Sc. joined Liquidia in 2007 where he serves as Senior Vice President of Manufacturing Operations. Michael brings more than 20 years of experience across all phases of drug and drug-device combination product development to his role at Liquidia where he manages all aspects of the company’s manufacturing operations, which, in part, led to the filing of its first NDA. Prior to joining Liquidia, Michael worked as both a Quality Engineer and Manufacturing Engineer with Boston Scientific in the company’s Stent Manufacturing Division where he was responsible for the transfer and validation of new products from process development to manufacturing. Here, he also served on the site FDA compliance counsel for the company’s Interventional Cardiology Division. Prior to his role at Boston Scientific, Michael worked for seven years in process development and scale-up in the telecommunications industry with Sony Ericsson and the semiconductor industry with Cree, Inc. Michael holds a Master of Science in Materials Engineering from North Carolina State University and a Bachelor of Science in Applied Science-Biomaterials from the University of North Carolina at Chapel Hill.

Beth Lang joined Liquidia in 2025 where she serves as Senior Vice President of Global Regulatory Affairs. Beth brings more than 25 years of extensive regulatory strategy expertise to her role at Liquidia where she is responsible for the management, development, implementation and coordination of the company’s regulatory affairs organization. Previously, Beth worked at Priovant Therapeutics where she was responsible for leading all aspects of the company’s regulatory strategy and operations in support of various autoimmune diseases. Prior to this, Beth provided strategic regulatory support to three biopharma companies, served as SVP of Regulatory Affairs and Pharmacovigilance at Enzyvant Therapeutics (formerly Altavant), and held several regulatory roles of increasing responsibility at biotech and global pharmaceutical companies of varying size and focus. Beth holds a Master of Business Administration in Leadership Studies from Marquette University and a Bachelor of Science with honors from University of Illinois at Urbana-Champaign.  

Christian Perez Font joined Liquidia in 2022 where he serves as Senior Vice President, Chief Compliance Officer and Associate General Counsel, leading the company’s ethics, compliance and privacy functions. Prior to joining Liquidia, he was outside counsel to the company and a founding partner at Thinkeen Legal, a boutique law firm specializing in corporate and commercial law,  domestic and cross-border transactions and compliance, with a focus on healthcare companies. Christian also held in-house roles of increasing responsibility at OPKO Health where he was Global Chief Compliance Officer, at Olympus Corporation of the Americas where he  led the compliance function for the Latin America Region and at Baxter International where he served as Corporate Counsel and Lead Bioscience Counsel for the Canada/Latam region, which included more than 30 jurisdictions with over 4,300 employees, four manufacturing plants and a shared services center. Previously, he was a partner at Baker & McKenzie, one of the largest law firms in the world focusing on mergers and acquisitions with significant focus in the healthcare space, and was also an associate at Arnold & Porter’s corporate and international group, in Washington, D.C. Christian holds an Bachelor of Laws from Andrés Bello Catholic University, a Juris Doctor , cum laude, from University of Miami School of Law and a Master of Laws from Georgetown University Law Center. Christian is a member of the Florida and District of Columbia bars.

Mike Post joined Liquidia in 2023 where he serves as Senior Vice President of Marketing. In this role, he leads the commercial brand strategy and marketing for Liquidia and its products. Mike has more than two decades of successful biopharmaceutical commercial and product launch experience with a focus on specialty drug-device delivery and combinations. Mike’s experiences include Chief Commercial Officer at Dosentrx, Inc., Vice President and General Manager of the Pain Business Unit at Jazz Pharmaceuticals, Vice President of Marketing at CNS Therapeutics, and a variety of sales and marketing roles at Eli Lilly. Mike holds a Master of Business Administration from the University of Michigan and a Bachelor of Science from Miami University.

Matt Snow joined Liquidia in 2022 where he serves as Senior Vice President of Sales. In this role, Matt leads the commercial sales organization and is responsible for sales strategy and execution. With more than 20 years of experience leading high-performing commercial teams across rare, ultra-rare, and specialty pharmaceutical markets, Matt has a proven track record of building and scaling sales organizations, successfully launching and relaunching complex therapies, and driving sustained growth. He has held leadership roles at SOBI, Insmed and United Therapeutics. Matt holds a Bachelor of Science in Marketing from the University of Utah.